ALK B ALK-ABELLO A/S

Invitation to the presentation of ALK’s first quarter results on Friday 3 May 2024

Invitation to the presentation of ALK’s first quarter results on Friday 3 May 2024

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its first quarter results in the morning of 3 May 2024.

Later same day, the company will host a presentation for investors and analysts at 12:30 CET, where ALK’s management will comment on the first quarter results and outlook and be available for questions.

ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR.

Live audio webcast

The meeting will be audio webcasted live and be available for replay on ALK’s website

Conference call

If you wish to participate via telephone, please register for the conference call by using this link: and follow the instructions. You will receive an email from with dial-in details, including a passcode and a pin code. Please make sure to whitelist  

and/or check your spam filter. We advise you to register on the day before the call at the latest.

Presentation

The presentation slides will be available on shortly before the meeting starts.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen. Find more information at

Attachment



EN
24/04/2024

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Morten Larsen
  • Peter Sehested
05/02/24 May 2, 2024 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Three-month interim report (Q1) 2024 (unaudited) - English version onl...

Three-month interim report (Q1) 2024 (unaudited) - English version only Bemærk venligst, at rapporten udelukkende forefindes på engelsk. Company release No. 11/2024 ALK delivers 10% organic revenue growth with operating profit up 41% in Q1 and upgrades outlookThe growth in ALK's overall sales was primarily driven by the European tablet sales, which were boosted by the inflow of new patients and improved pricing. Sales outside Europe had a soft start to the year, partly due to temporary sales fluctuations and phasing of product shipments to International markets. Outlook for full-year reve...

May 2, 2024 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Three-month interim report (Q1) 2024 (unaudited) 

Three-month interim report (Q1) 2024 (unaudited)  Company release No. 11/2024 ALK delivers 10% organic revenue growth with operating profit up 41% in Q1 and upgrades outlookThe growth in ALK's overall sales was primarily driven by the European tablet sales, which were boosted by the inflow of new patients and improved pricing. Sales outside Europe had a soft start to the year, partly due to temporary sales fluctuations and phasing of product shipments to International markets. Outlook for full-year revenue growth now expected at 10-13% (previously 9-12%). Performance highlights Co...

May 2, 2024 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK opjusterer sine forventninger til salget for helåret

ALK opjusterer sine forventninger til salget for helåret ALK opjusterer sine salgsforventninger for helåret ALK (ALKB:DC / OMX: ALK B / AKBLF) annoncerede i dag, at salgsforventningerne for helåret 2024 er blevet opjusteret. Omsætningen forventes nu at vokse med 10-13% i lokale valutaer (tidligere: 9-12%), primært for at afspejle den seneste udvikling inden for salg af tabletter i Europa. EBIT-marginen forventes stadig at forbedres til 17-19%, men resultatprognosen inkluderer nu engangsomkostninger på cirka 60 millioner DKK relateret til optimeringsinitiativer. Disse omkostninger ikke va...

May 2, 2024 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK upgrades its full-year revenue outlook

ALK upgrades its full-year revenue outlook ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the 2024 full-year financial outlook has been updated. Revenue is now expected to grow by 10-13% in local currencies (previously: 9-12%). The full-year financial outlook has been updated mainly to reflect the recent development in European tablet sales. The EBIT margin is still expected to improve to 17-19% but the earnings outlook now includes one-off costs of approximately DKK 60 million related to optimization initiatives, whereas no such costs were included in the original outlook from F...

May 2, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch